PURPOSE: To assess the efficacy and safety of intradetrusor botulinum toxin type A injections (IBTI) for idiopathic overactive bladder (iOAB) in non-neurological adults with an artificial urinary sphincter (AUS). MATERIALS AND METHODS: We retrospectively selected, in the 11 French centers, members of a collaborative network (GENULF (Groupe d'étude de neuro-urologie de langue francaise)), the patients who had had an artificial urinary sphincter implantation and who had subsequently developed iOAB requiring IBTI. This study was approved by the French association of urology ethics committee (no 2018012). RESULTS: Between 2006 and 2020, 33 patients were included from 5 French centers. Mean follow-up after the first IBTI was 47 months. The average age of the studied population was 68 years, with 70% of females. A complete resolution of symptoms at optimal IBTI dose was experienced by 21 (64%) patients. Seven (21%) patients had partial improvement. Five non-responder patients (15%) had no improvement at all. Maximum cystometric bladder capacity was 240 ml pre-IBTI and 335 ml post IBTI. Discontinuation free survival at 60 months was 50%. Two erosions occurred during the 6 months following an IBTI both in male patients with a perineal implantation. There were four AUS balloon perforations that occurred during the 6 months following an IBTI, all of them in female patients. CONCLUSIONS: IBTI has a good efficacy for the treatment of iOAB in patients with an AUS. However, both patients and practicians must be aware of the risk of rare and usually mild complications.
PURPOSE: To assess the efficacy and safety of intradetrusor botulinum toxin type A injections (IBTI) for idiopathic overactive bladder (iOAB) in non-neurological adults with an artificial urinary sphincter (AUS). MATERIALS AND METHODS: We retrospectively selected, in the 11 French centers, members of a collaborative network (GENULF (Groupe d'étude de neuro-urologie de langue francaise)), the patients who had had an artificial urinary sphincter implantation and who had subsequently developed iOAB requiring IBTI. This study was approved by the French association of urology ethics committee (no 2018012). RESULTS: Between 2006 and 2020, 33 patients were included from 5 French centers. Mean follow-up after the first IBTI was 47 months. The average age of the studied population was 68 years, with 70% of females. A complete resolution of symptoms at optimal IBTI dose was experienced by 21 (64%) patients. Seven (21%) patients had partial improvement. Five non-responder patients (15%) had no improvement at all. Maximum cystometric bladder capacity was 240 ml pre-IBTI and 335 ml post IBTI. Discontinuation free survival at 60 months was 50%. Two erosions occurred during the 6 months following an IBTI both in male patients with a perineal implantation. There were four AUS balloon perforations that occurred during the 6 months following an IBTI, all of them in female patients. CONCLUSIONS: IBTI has a good efficacy for the treatment of iOAB in patients with an AUS. However, both patients and practicians must be aware of the risk of rare and usually mild complications.
Authors: José Tadeu Nunes Tamanini; Letícia Valério Pallone; Marair Grácio Ferreira Sartori; Manoel João Batista Castello Girão; Jair Lício Ferreira Dos Santos; Yeda Aparecida de Oliveira Duarte; Philip E V A van Kerrebroeck Journal: Neurourol Urodyn Date: 2017-06-30 Impact factor: 2.696
Authors: Kushan D Radadia; Nicholas J Farber; Brian Shinder; Charles F Polotti; Lee J Milas; Hari S G R Tunuguntla Journal: Urology Date: 2017-10-12 Impact factor: 2.649
Authors: David D Thiel; Paul R Young; Gregory A Broderick; Michael G Heckman; Michael J Wehle; Todd C Igel; Steven P Petrou Journal: Urology Date: 2007-02 Impact factor: 2.649
Authors: Jaspreet S Sandhu; Benjamin Breyer; Craig Comiter; James A Eastham; Christopher Gomez; Daniel J Kirages; Chris Kittle; Alvaro Lucioni; Victor W Nitti; John T Stoffel; O Lenaine Westney; M Hassan Murad; Kurt McCammon Journal: J Urol Date: 2019-07-08 Impact factor: 7.450